Latest Headlines

Latest Headlines

GSK, Actelion put failed sleep drug to rest

GlaxoSmithKline and Actelion have discontinued the development of the insomnia drug almorexant, a dual orexin receptor antagonist, over concerns about patients' tolerance of the drug. GSK inked a

Sleep drug's safety issues torpedo Actelion shares

Shares of Switzerland's Actelion (ATLN) sank after the developer announced that its experimental sleep drug had hit its primary endpoint in a late-stage trial but raised certain unspecified safety

GSK inks $3.25B insomnia pact with Actelion

GlaxoSmithKline has partnered with Actelion in a whopping 3.3 billion Swiss franc pact ($3.25 billion) covering a new insomnia therapy now in late-stage studies. Actelion nabs 150 million francs